Roivant Sciences Past Earnings Performance
Past criteria checks 3/6
Roivant Sciences has been growing earnings at an average annual rate of 40.4%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 28.8% per year. Roivant Sciences's return on equity is 65.6%, and it has net margins of 3484.9%.
Key information
40.4%
Earnings growth rate
49.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 28.8% |
| Return on equity | 65.6% |
| Net Margin | 3,484.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21
These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year
Aug 21Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M
Aug 15An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued
Aug 12Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Jun 30Revenue & Expenses Breakdown
How Roivant Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 125 | 4,349 | 687 | 0 |
| 31 Dec 23 | 123 | 4,352 | 643 | 0 |
| 30 Sep 23 | 103 | -1,096 | 614 | 0 |
| 30 Jun 23 | 79 | -1,084 | 608 | 0 |
| 31 Mar 23 | 61 | -1,124 | 601 | 0 |
| 31 Dec 22 | 43 | -1,245 | 614 | 0 |
| 30 Sep 22 | 50 | -1,178 | 561 | 0 |
| 30 Jun 22 | 52 | -1,095 | 491 | 0 |
| 31 Mar 22 | 55 | -845 | 425 | 0 |
| 31 Dec 21 | 61 | -1,085 | 367 | 0 |
| 30 Sep 21 | 43 | -1,061 | 314 | 0 |
| 30 Jun 21 | 30 | -888 | 286 | 0 |
| 31 Mar 21 | 24 | -809 | 260 | 0 |
| 31 Dec 20 | 72 | -360 | 259 | -199 |
| 31 Mar 20 | 68 | -456 | 336 | 0 |
| 31 Mar 19 | 2 | -613 | 237 | 513 |
Quality Earnings: ROIV has a high level of non-cash earnings.
Growing Profit Margin: ROIV became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ROIV has become profitable over the past 5 years, growing earnings by 40.4% per year.
Accelerating Growth: ROIV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ROIV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ROIV's Return on Equity (65.6%) is considered outstanding.